# ANVS — Annovis Bio Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ANVS  
**Sources:** 19  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-anvs-annovis-bio-inc-catalysts-narrative-risks-6143

---

## Company Snapshot

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern/Berwyn, Pennsylvania, developing the investigational once-daily oral therapy **buntanetap** (announced as formerly "posiphen" [[1]](https://finance.yahoo.com/healthcare/articles/annovis-host-corporate-webinar-september-120000502.html), [[2]](https://markets.businessinsider.com/news/stocks/annovis-announces-partnership-with-weave-bio-ai-regulatory-platform-in-preparation-of-nda-for-buntanetap-in-alzheimer-s-disease-1036567137)) for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). It is not part of a major headline index [[5]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/annovis-bio-stock-reacts-to-webinar-plan-and-steep-discount-to-analyst/70057955). Below is a point-in-time review as of 2026-10-04; it is descriptive, not investment advice.

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-anvs-annovis-bio-inc-catalysts-narrative-risks-6143 (free to sign up)._
